Could This Vitamin Stall MS?

When you’re living with multiple sclerosis (MS)—or supporting someone who is—every small win matters.

This unpredictable autoimmune disease can bring profound fatigue, pain, vision problems, and difficulty with movement.

And while there are medications that help, they can come with heavy side effects, and the journey often feels like a waiting game.

So when a new study shows that something as simple—and affordable—as a vitamin might actually slow the progression of early MS, we sit up and pay attention.

You’ve heard us sing vitamin D’s praises before—and for good reason. From supporting immunity to protecting your bones and brain, this powerhouse nutrient plays a vital role in your overall health.

Now, a new study just gave us another reason to keep vitamin D in the spotlight.

Researchers from Yale are calling it a “powerful victory” for high-dose vitamin D in the fight against multiple sclerosis (MS)—a notoriously difficult disease to treat.

Here’s what made this trial different—and why the results are worth your attention…

Researchers enrolled 316 people with clinically isolated syndrome (CIS)—the earliest sign of MS, like a first episode of optic neuritis. Not everyone with CIS will go on to develop full MS, but many do.

Participants received either a high-dose vitamin D3 supplement (100,000 IU every 2 weeks) or a placebo. This is a very large dose, far above typical multivitamin levels. The trial followed participants for 2 years.

The results?

• Disease activity (measured by relapses or new lesions on MRI) was seen in 74% of placebo participants, compared to just 60% of those taking vitamin D.
• That’s a 14% absolute risk reduction—meaning you’d need to treat 7 people to help 1 avoid progression.
• The median time to disease progression was extended by about 7 months in the vitamin D group.

And here’s the kicker: there were no serious safety issues. No cases of high calcium or kidney damage in the vitamin D group.

The greatest benefits were seen in people who:

• Started with low vitamin D levels
• Had milder disease presentations
• Had no spinal cord lesions
• Did not receive high-dose steroid treatment

In other words, early intervention made all the difference.

Let’s be clear: we’re not always anti-drug. For many people, prescription medications are necessary—and even lifesaving.

But we are pro-information.

And for too long, Big Pharma has dominated the conversation around MS treatment. And while disease-modifying drugs can help, they’re expensive and can come with heavy side effects.

This study offers something different:

• A low-cost, low-risk intervention
• With real-world results
• Especially for those early in their MS journey

If you or someone you love has recently been diagnosed with MS—or even CIS—this study is worth bringing up with your doctor.

And while high-dose vitamin D isn’t something you should start on your own (too much can be harmful), it’s clear that testing your vitamin D levels and discussing targeted supplementation could make a meaningful difference.

To your informed health,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

Sources:

Wilson, P. (2025, March 10). A Rare Win for Vitamin D — This Time in MS. Medscape. https://www.medscape.com/viewarticle/rare-win-vitamin-d-this-time-ms-2025a10005ul